openPR Logo
Press release

B-cell Maturation Antigen (BCMA) Targeted Therapies Market Growth, Analysis, and Industry Forecast till 2025

08-07-2018 03:58 PM CET | Health & Medicine

Press release from: CMI Research

B-cell Maturation Antigen (BCMA) Targeted Therapies Market

The Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, by product type (CAR-T cell, bispecific antibodies, and antibody drug conjugates), and by indication (acute lymphoblastic leukemia, and multiple myeloma) has potential products in pipeline, as highlighted in a new report published by Coherent Market Insights. Increasing number of BCMA targeted therapies in pipeline and increasing prevalence of multiple myeloma are expected to favor growth of the B-cell maturation antigen (BCMA) targeted therapies market worldwide.

Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/190

Increasing recurrence of multiple myeloma has been a major obstacle. According to the National Cancer Institute, in 2016, around 75,000 patients globally were recorded to be suffering from relapsed or refractory multiple myeloma, with a relative survival rate of 5 years. According to American Cancer Society, as of 2017, around 30,280 multiple myeloma cases are estimated to be diagnosed, out of which around 12,590 deaths are estimated to occur. Multiple myeloma (MM) is the second most common hematological malignancy in the U.S. and European countries. According to American Cancer Society, in the U.S. the lifetime risk of contracting multiple myeloma is 1 in 143 (0.7%). B-cell maturation antigen (BCMA), is a cell surface protein that is expressed on the malignant plasma cells.

Browse through 130 Pages and an in-depth TOC on ‘B-cell Maturation Antigen (BCMA) Targeted Therapies, by Product type (Antibody Drug Conjugates, CAR-T Cells, and Bispecific Antibodies), by Indication (Acute Lymphoblastic Leukemia and Multiple Myeloma), and by Region

Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/190

According to the Cancer Research U.K., as of 2014, myeloma is estimated to be the 18th most common cancer in the U.K., with an estimated 5,500 new cases of multiple myeloma, reported around 15 new cases every day. Incidence rates for myeloma are projected to rise by 11% or 12 cases per 100,000 people by 2035. According to the National Center for Biotechnology Information, 2014, multiple myeloma represents 8.2% of all blood cancers in Africa.

Market players are actively investing in research and development of novel multiple myeloma therapies to develop alternatives for existing drugs. These therapies include chimeric antigen receptor T cells, antibody-drug conjugate, and bispecific antibodies. Preclinical and clinical trial results on these therapies have demonstrated potential benefits.

Key Takeaways of the Market:

According to the American Society of Clinical Oncology (ASCO), in 2016, multiple myeloma was the second most common blood cancer, after non-Hodgkin lymphoma, accounting for 1% of all kinds of malignancies globally, with 70 years being the median age of diagnosis

As there are no treatment option available for patients with recurrent cancer, development of therapy to treat relapsed and/or refractory multiple myeloma is expected to provide market players with lucrative opportunities

Some of the major players involved in the development of B-cell maturation antigen (BCMA) targeted therapies market are Celgene Corporation, GlaxoSmithKline plc, Novartis AG, Juno Therapeutics, Gilead Sciences. Inc., Amgen Inc., Affimed N.V, Poseida Therapeutics, Inc., and Autolus Ltd.

Ask for customization: https://www.coherentmarketinsights.com/insight/request-customization/190

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154
#3200

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release B-cell Maturation Antigen (BCMA) Targeted Therapies Market Growth, Analysis, and Industry Forecast till 2025 here

News-ID: 1167132 • Views: 374

More Releases from CMI Research

Wearable Patch Industry Adoption of Innovative Offerings and Forecast 2019-2027
Coherent Market Insights has recently updated its massive report catalogue by adding a fresh study titled "Global Wearable Patch Market: Industry Analysis, Size, Share, Growth, Trends, & Forecast 2019-2027". This business intelligence study On current Growth as well as future status during the mentioned forecast period of 2027. The report also targets important facets such as market drivers, challenges, latest trends, and opportunities associated with the growth of manufacturers in the
Hemodialysis Industry Showcase Attractive Growth Opportunities and Forecast 2019 …
Coherent Market Insights has recently updated its massive report catalogue by adding a fresh study titled "Global Hemodialysis Market: Industry Analysis, Size, Share, Growth, Trends, & Forecast 2019-2027". This business intelligence study On current Growth as well as future status during the mentioned forecast period of 2027. The report also targets important facets such as market drivers, challenges, latest trends, and opportunities associated with the growth of manufacturers in the global
Breast Reconstruction Industry Positive Long-Term Growth Outlook and Forecast 20 …
Coherent Market Insights has recently updated its massive report catalogue by adding a fresh study titled "Global Breast Reconstruction Market: Industry Analysis, Size, Share, Growth, Trends, & Forecast 2019-2027". This business intelligence study On current Growth as well as future status during the mentioned forecast period of 2027. The report also targets important facets such as market drivers, challenges, latest trends, and opportunities associated with the growth of manufacturers in the
Elderly Nutrition Industry Emerging Growth, Trend and Forecast to 2027
Coherent Market Insights has recently updated its massive report catalogue by adding a fresh study titled "Global Elderly Nutrition Market: Industry Analysis, Size, Share, Growth, Trends, & Forecast 2019-2027". This business intelligence study On current Growth as well as future status during the mentioned forecast period of 2027. The report also targets important facets such as market drivers, challenges, latest trends, and opportunities associated with the growth of manufacturers in the

All 5 Releases


More Releases for BCMA

B-cell Maturation Antigen (BCMA) Targeted Therapies Market Strategies, Technolog …
Recurrence of multiple myeloma has been a highly prevalent health condition, which requires novel and effective immunotherapeutic treatment. According to Leukemia Research by Elsevier, as of 2014, the incidence of multiple myeloma is estimated to be around 120,000 cases per year, with a global prevalence of over one million cases. B-cell maturation antigen (BCMA), is a cell surface protein that is expressed on the malignant plasma cells. This cell surface
B-cell Maturation Antigen (BCMA) Targeted Therapies Market - Insights, Size, Ana …
The Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, by product type (CAR-T cell, bispecific antibodies, and antibody drug conjugates), and by indication (acute lymphoblastic leukemia, and multiple myeloma) has potential products in pipeline, as highlighted in a new report published by Coherent Market Insights. Increasing number of BCMA targeted therapies in pipeline and increasing prevalence of multiple myeloma are expected to favor growth of the B-cell maturation antigen (BCMA)
B-cell Maturation Antigen (BCMA) Targeted Therapies Market, by Product Type, Ind …
The Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, by product type (CAR-T cell, bispecific antibodies, and antibody drug conjugates), and by indication (acute lymphoblastic leukemia, and multiple myeloma) has potential products in pipeline, as highlighted in a new report published by Coherent Market Insights. Increasing number of BCMA targeted therapies in pipeline and increasing prevalence of multiple myeloma are expected to favor growth of the B-cell maturation antigen (BCMA)
B Cell Maturation Antigen (BCMA) Targeted Therapies Market Poised for Steady Gro …
B-cell maturation antigen (BCMA) is a protein, also called tumor necrosis factor receptor superfamily member 17 (TNFRSF17) or CD269 antigen, which is encoded in humans by TNFRSF17 gene. BCMA is an essential member of tumor necrosis factor receptor super family and is preferentially expressed in B lymphocytes. B-cell maturation antigen receptor is necessary for B-cell development and also in autoimmune response. This receptor specially binds to tumor necrosis factor (TNF)
B-Cell Maturation Antigen (BCMA) Targeted Therapies Market - Global Industry Ins …
Multiple myeloma is an incurable disease of plasma cells, which needs some intervention by clinical researchers. However, there have been recent success in developing such therapy that can be effective in hematologic malignancies such as chimeric antigen receptor CAR-T cell therapy, which is expected to be promising in cancer treatment. However, researchers have found little success in finding a specific target antigen under CAR T-cell therapies for treating multiple myeloma.
B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Research Report | For …
B-cell maturation antigen (BCMA) is a protein, also called tumor necrosis factor receptor superfamily member 17 (TNFRSF17) or CD269 antigen, which is encoded in humans by TNFRSF17 gene. BCMA is an essential member of tumor necrosis factor receptor super family and is preferentially expressed in B lymphocytes. B-cell maturation antigen receptor is necessary for B-cell development and also in autoimmune response. This receptor specially binds to tumor necrosis factor (TNF)